Theravance Biopharma Inc (TBPH) Stock Analysis & Investment Frameworks
Theravance Biopharma Inc (TBPH) stock analysis on Invetso. Review Theravance Biopharma Inc’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Theravance Biopharma Inc Company Overview
- Exchange: NASDAQ
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Theravance Biopharma Inc Key Financial Metrics
- Market Cap: $884.18M
- Revenue: $107.46M
- P/E Ratio: 8.35
- ROE: 19.40%
- ROIC: 0.95%
- Dividend Yield: N/A
About Theravance Biopharma Inc
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
Theravance Biopharma Inc Investment Frameworks
Invetso analyzes Theravance Biopharma Inc (TBPH) across the following frameworks:
- Theravance Biopharma Inc 10Y Growth Potential
- Theravance Biopharma Inc Scenario Analysis
- Theravance Biopharma Inc Risks & Opportunities
- Theravance Biopharma Inc Economic Moat
- Theravance Biopharma Inc Business Model
- Theravance Biopharma Inc Management
- Theravance Biopharma Inc SWOT Analysis
- Theravance Biopharma Inc Porter's 5 Forces
- Theravance Biopharma Inc PESTLE Analysis
- Theravance Biopharma Inc ESG Analysis